Telix Pharmaceuticals (TLPPF) Projected to Post Earnings on Friday

Telix Pharmaceuticals (OTCMKTS:TLPPF) is expected to be announcing its results before the market opens on Friday, February 20th. Analysts expect the company to announce earnings of $0.0328 per share and revenue of $322.8750 million for the quarter.

Telix Pharmaceuticals Stock Performance

OTCMKTS TLPPF opened at $6.50 on Thursday. The stock’s 50 day simple moving average is $7.53 and its 200 day simple moving average is $9.19. Telix Pharmaceuticals has a one year low of $5.91 and a one year high of $24.85.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.